Lazard Asset Management
SLDB icon

Lazard Asset Management’s Solid Biosciences SLDB Stock Holding History

Lazard Asset Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-81
Closed – – 2557
2024
Q4 		$0 Hold
81
– – ﹤0.01% 2518
2024
Q3 		$0 Sell
81
-68
-46% -$551 ﹤0.01% 2439
2024
Q2 		$0 Sell
149
-1,480
-91% -$13.3K ﹤0.01% 2412
2024
Q1 		$21K Buy
+1,629
New +$15.2K ﹤0.01% 1836
2023
Q4 		– Sell
-2,332
Closed -$5K – 2444
2023
Q3 		$5K Buy
2,332
+116
+5% +$450 ﹤0.01% 2177
2023
Q2 		$11K Buy
2,216
+127
+6% +$715 ﹤0.01% 2177
2023
Q1 		$9K Buy
+2,089
New +$12.6K ﹤0.01% 2134

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lazard Asset Management's SLDB Position: Q1 2025 in Review

Lazard Asset Management sold out of Solid Biosciences (SLDB) in Q1 2025, closing a stake of 81 shares.

Lazard Asset Management first reported a position in SLDB in Q1 2023 and held it in 7 quarters. The position peaked at $21K in Q1 2024. 124 funds tracked by Wall St. Rank hold SLDB as of Q1 2025.

  • Lazard Asset Management reported no remaining Solid Biosciences position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 81 Solid Biosciences shares in Q1 2025.
  • Lazard Asset Management first reported a position in Solid Biosciences in Q1 2023 and held it in 7 quarters.
  • Lazard Asset Management's Solid Biosciences position peaked at $21K in Q1 2024.
  • 124 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.